The sphingosine kinase inhibitor N,N-dimethylsphingosine inhibits neointimal hyperplasia

British Journal of Pharmacology

Volumn 159, Issue 3, 2010, Pages 543-553

  McDonald, Robert A ^a   Pyne, Susan ^a   Pyne, Nigel J ^a   Grant, Anne ^a   Wainwright, Cherry L ^a   Wadsworth, Roger M ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Anti proliferative; Extracellular signal regulated protein kinase; Intimal thickening; Protein kinase C; Restenosis; Smooth muscle cells (vascular); Sphingosine; Sphingosine kinase

Indexed keywords

DEXTRO ERYTHRO N,N DIMETHYLSPHINGOSINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N,N DIMETHYLSPHINGOSINE; PROTEIN KINASE B; PROTEIN KINASE C; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DNA SYNTHESIS; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; FETAL CALF SERUM; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTRAVASCULAR CATHETER; MALE; MORPHOMETRICS; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SWINE; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOPTOSIS; BALLOON DILATATION; CELL PROLIFERATION; HYPERPLASIA; LYSOPHOSPHOLIPIDS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SPHINGOSINE; SUS SCROFA; TUNICA INTIMA;

EID: 76449088823     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00533.x     Document Type: Article

References (30)

1. Alemany R, van Koppen CJ, Danneberg K, Ter Braak M, Meyer zu Heringdorf D (2007). Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol 374 : 413 428.
2. Bourbon NA, Sandirasegarane L, Kester M (2002). Ceramide-induced inhibition of Akt is mediated through protein kinase Cζ: implications for growth arrest. J Biol Chem 277 : 3286 3292.
3. Charles R, Sandirasegarane L, Yun J, Bourbon N, Wilson R, Rothstein RP et al. (2000). Ceramide-coated balloon catheters limit neointimal hyperplasia after stretch injury in carotid arteries. Circ Res 87 : 282 288.
4. Chun J, Goetzl EG, Hla T, Igarashi Y, Lynch KR, Moolenaar W et al. (2002). IUPHAR XXXIV Lysophospholipid receptor nomenclature. Pharmacol Rev 54 : 265 269.
5. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S et al. (1996). Suppression of ceramide-mediated programmed cell death by sphingosine 1-phosphate. Nature 381 : 800 803.
6. Edsall LC, Van Brocklyn JR, Cuvillier O, Kleuser B, Spiegel S (1998). N,N-dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: Modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry 37 : 12892 12898.
7. George SJ, Baker AH, Angelini AB, Newby AC (1998). Gene transfer of tissue inhibitor of metalloproteinase 2 inhibits metalloproteinase activity and neointima formation in human saphenous vein. Gene Ther 5 : 1552 1560.
8. Hannun YA, Bell R (1987). Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science 235 : 670 674.
9. Hannun YA, Obeid LM (2008). Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9 : 139 150.
10. Katsuma S, Hada Y, Ueda T, Shiojima S, Hirasawa A, Tanoue A et al. (2002). Signalling mechanisms in sphingosine 1-phosphate-promoted mesangial cell proliferation. Genes Cells 7 : 1217 1230.
11. Kennedy S, Wadsworth RM, Wainwright CL (2006). Locally administered anti-proliferative drugs inhibit hypercontractility to serotonin in balloon-injured pig coronary artery. Vascul Pharmacol 44 : 363 371.
12. Kim JW, Kim YW, Inagaki Y, Hwang YA, Mitsutake S, Ryu YW et al. (2005). Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases. Bioorg Med Chem 13 : 3475 3485.
13. Kimura T, Sato K, Malchinkhuu E, Tomura H, Tamama K, Kuwabara A et al. (2003). High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 23 : 1283 1288.
14. Kolesnick R (2002). The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 110 : 3 8.
15. Limaye V (2008). The role of sphingosine kinase and sphingosine-1- phosphate in the regulation of endothelial cell biology. Endothelium 15 : 101 112.
16. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R et al. (2005). SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 280 : 37118 37129.
17. Pyne S, Pyne NJ (2000). Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 349 : 385 402.
18. Pyne NJ, Pyne S (2008). Sphingosine 1-phosphate, lysophosphatidic acid and growth factor signalling and termination. Biochim Biophys Acta 1781 : 467 476.
19. Pyne S, Lee SC, Long J, Pyne NJ (2009). Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal 21 : 14 21.
20. Sherr CJ (1996). Cancer cell cycles. Science 274 : 1672 1677.
21. Spiegel S, Milstien S (2003). Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4 : 397 407.
22. Steffel J, Tanner FC (2007). Biological effects of drug-eluting stents in the coronary circulation. Herz 32 : 268 273.
23. Takabe K, Paugh SW, Milstien S, Spiegel S (2008). 'Inside-out' signalling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60 : 181 195.
24. Voisard R, Jensch V, Baur R, Hoher M, Hombach V (1995). A coronary porcine organ culture system for studies of post-angioplasty cell proliferation. Coron Artery Dis 6 : 657 665.
25. Wamhoff BR, Lynch KR, Macdonald TL, Owens GK (2008). Sphingosine-1- phosphate receptor subtypes differentially regulate smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 8 : 1454 1461.
26. Windecker S, Juni P (2008). Safety of drug-eluting stents. Nat Clin Pract Cardiovasc Med 5 : 316 328.
27. Work LM, McPhaden AR, Pyne NJ, Pyne S, Wadsworth RM, Wainwright CL (2001). Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty. Circulation 104 : 1538 1543.
28. Xu CB, Zhang YP, Stenman E, Edvinsson L (2002). d-erythro-N,N- dimethylsphingosine inhibits bFGF-induced proliferation of cerebral, aortic and coronary smooth muscle cells. Atherosclerosis 164 : 237 243.
29. Yatomi Y, Ruan F, Megidish T, Toyokuni T, Hakomori S, Igarashi Y (1996). N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry 35 : 626 633. (Pubitemid 26032716)
30. Zohlnhofer D, Richter T, Neumann F, Nuhrenberg T, Wessely R, Brandl R et al. (2001). Transcriptome analysis reveals a role of interferon gamma in human neointima formation. Mol Cell 7 : 1059 1069.